Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -- |
| Cost of Revenue | 26.30% | 23.10% | 20.91% | 29.79% | 36.97% |
| Gross Profit | -28.12% | -25.00% | -22.89% | -32.09% | -35.03% |
| SG&A Expenses | 11.07% | 25.24% | 45.27% | 61.14% | 86.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.01% | 23.68% | 26.95% | 37.31% | 48.08% |
| Operating Income | -23.27% | -25.06% | -28.50% | -39.15% | -46.57% |
| Income Before Tax | -21.97% | -20.24% | -59.88% | -77.27% | -97.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.97% | -20.24% | -59.88% | -77.27% | -97.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.97% | -20.24% | -59.88% | -77.27% | -97.36% |
| EBIT | -23.27% | -25.06% | -28.50% | -39.15% | -46.57% |
| EBITDA | -24.12% | -26.29% | -30.03% | -41.38% | -49.43% |
| EPS Basic | -4.06% | 1.24% | -105.27% | -109.25% | -120.71% |
| Normalized Basic EPS | -3.93% | 1.26% | 83.54% | 92.35% | 94.68% |
| EPS Diluted | -4.06% | 1.24% | -1,483.80% | 86.39% | 92.39% |
| Normalized Diluted EPS | -3.93% | 1.26% | -0.72% | 87.85% | 92.86% |
| Average Basic Shares Outstanding | 16.48% | 21.40% | 60.74% | 124.63% | 303.31% |
| Average Diluted Shares Outstanding | 16.48% | 21.40% | 21.42% | 52.10% | 111.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |